Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.

Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an Investigational Device Exemption ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has ...

ROME (Reuters) - EssilorLuxottica said on Monday it received a green light from the U.S. Food and Drug Administration (FDA) ...

Christophe Gardella, Ph.D., chief technical officer for BrightHeart, the Paris-based manufacturer of the AI-based software BrightHeart received FDA 510(k) clearance for its first AI software product ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

This growth has brought controversy. Photo illustration: Alexander Hotz U.S. health officials cleared America’s most popular nicotine pouch to stay on the market, saying Zyn’s benefit as a ...

The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, until January 2028, to comply with the change. Red 3, also known as ...

The FDA authorized the 20 Zyn products under a premarket tobacco product application process granted under a 2009 tobacco control law. Because Zyn includes nicotine, it must abide by the same ...